Post-market Surveillance Study With the HYPERION Hip Endoprosthesis System in Defect Reconstruction

Inclusion Criteria: * Patient age at least 18 years * Fully conscious and capable patients * Signed informed consent * Stationary treatment * Merle d'Aubigné \< 12 Points, WOMAC Score \> 25 Points * Patients with at least one of the following indications: Indications for primary hip replacement: * Non-inflammatory diseases of the joints such as osteoarthritis and avascular necrosis (head necrosis) * Rheumatoid arthritis * Functional deformities * Provision of non-endoprosthetic previous operations of the hip joint (e.g., transposition osteotomies) * Treatment of pseudarthrosis, femoral neck and trochanter fractures, as well as fractures of the proximal femur affecting the head, which can not be treated by other techniques Revision THA: * Revision of endoprosthesis-treated hips as a result of septic or aseptic loosening, sub- and periprosthetic fractures or material failure (eg fracture of the prosthesis) * Bridging of large bone defects (precondition: suitable proximal bone situation for a stable anchorage), i.e. for tumors Exclusion Criteria: * Infections * Patients under 18 years * Pregnant or breastfeeding patients * Known alcohol abuse (at least 20 g alcohol per day for women and at least 40 g per day for men) or drug abuse * Legal incapacity or restricted capacity * Participation in another clinical trial within the last 30 days or planned participation in another clinical trial within the next 3 months * Patients who are unable to attend to follow-up